Xenome adds Cherrington to board
- 11 August, 2009 16:30
- Comments
Experienced biotech board jockey, Dr Julie Cherrington, has joined the board of the privately listed Xenome as an independent, non-executive director. The appointment was effective as of August 1.
Cherrington has held numerous posts in Australia and the United States in biotechnology companies, including seats on the boards of ChemGenex and Progen Pharmceuticals.
She is also president of San Diego-based biopharmceutical company, Phenomix Corporation. Prior to her appointment as president, Cherrington served as the executive vice president of research and development at Phenomix. She has also held research positions at SUGEN and Gilead Sciences.
Xenome focuses on discovery and development of peptide-based therapeutics derived from venom. Its lead product is Xen2174, a novel conopeptide analogue for the treatment of moderate to severe pain.
Xenome was profiled in the September/October 2008 issue of Australian Life Scientist.
-
An Introduction to Molecular Biotechnology - Molecular Fundamentals, Methods and Applications in Modern Biotechnology
-
Fluorescence Applications in Biotechnology and Life Sciences
-
Statistics for Terrified Biologists
-
Molecular Forensics
-
The Scientific American a Day in the Life of Your Brain
-
Molecular & Cell Biology for Dummies
-
Writing Scientific Research Articles - Strategy and Steps
-
Dictionary of DNA and Genome Technology 2E
-
Proteins - Structure and Function
Comments
Post new comment